The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE
Open accessAbstract
Autoantibodies against double-stranded DNA (dsDNA) and nucleosomes represent a hallmark of systemic lupus erythematosus (SLE). However, the mechanisms involved in breaking the immunological tolerance against these poorly immunogenic nuclear components are not fully understood. Impaired phagocytosis of apoptotic cells with consecutive release of nuclear antigens may contribute to the immune pathogenesis. The architectural chromosomal protein and proinflammatory mediator high mobility group box protein 1 (HMGB1) is tightly attached to the chromatin of apoptotic cells. We demonstrate that HMGB1 remains bound to nucleosomes released from late apoptotic cells in vitro. HMGB1–nucleosome complexes were also detected in plasma from SLE patients. HMGB1-containing nucleosomes from apoptotic cells induced secretion of interleukin (IL) 1β, IL-6, IL-10, and tumor necrosis factor (TNF) α and expression of costimulatory molecules in macrophages and dendritic cells (DC), respectively. Neither HMGB1-free nucleosomes from viable cells nor nucleosomes from apoptotic cells lacking HMGB1 induced cytokine production or DC activation. HMGB1-containing nucleosomes from apoptotic cells induced anti-dsDNA and antihistone IgG responses in a Toll-like receptor (TLR) 2–dependent manner, whereas nucleosomes from living cells did not. In conclusion, HMGB1–nucleosome complexes activate antigen presenting cells and, thereby, may crucially contribute to the pathogenesis of SLE via breaking the immunological tolerance against nucleosomes/dsDNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Self-citationRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Self-citationHMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385
Toll-like receptors in the induction of the innate immune response
Aderem, A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,064
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041
Immunosuppressive effects of apoptotic cells
Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R., & Girkontaite, I. (1997) · Nature · doi:10.1038/37022 · Cited by 1,787
Self-citationCasciola-Rosen, L. A., Anhalt, G., & Rosen, A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1317 · Cited by 1,717
Park, J. S., Svetkauskaite, D., He, Q., Kim, J.-Y., Strassheim, D., Ishizaka, A., & Abraham, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306793200 · Cited by 1,562
Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
“The two DNA-binding domains of HMGB1 have distinct biological activities: The B box recapitulates the inflammatory activities of the full-length protein, whereas the A box antagonizes it.”
InfluentialHMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
PAMP s and DAMP s: signal 0s that spur autophagy and immunity
Tang, D., Kang, R., Coyne, C. B., Zeh, H. J., & Lotze, M. T. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01146.x · Cited by 1,221
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
Self-citationDAMPening Inflammation by Modulating TLR Signalling
Piccinini, A. M., & Midwood, K. S. (2010) · Mediators of Inflammation · doi:10.1155/2010/672395 · Cited by 973
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease
Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.222 · Cited by 689
DAMPs from Cell Death to New Life
Vénéreau, E., Ceriotti, C., & Bianchi, M. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00422 · Cited by 666
Self-citationThe role of defective clearance of apoptotic cells in systemic autoimmunity
Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A., & Herrmann, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.46 · Cited by 627
Self-citationThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
“Indeed, various FcR+ cells can release HMGB-1 that increases cross-priming and activation of DC in both mice and humans (Apetoh et al., 2007; Urbonaviciute et al., 2008).”
BackgroundAlarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
Accessory molecules for Toll-like receptors and their function
Lee, C. C., Avalos, A. M., & Ploegh, H. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3151 · Cited by 439
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Release and activity of histone in diseases
Chen, R., Kang, R., Fan, X.-G., & Tang, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.337 · Cited by 419
Bianchi, M. E. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008585 · Cited by 416
Self-citationImmunological pathogenesis and treatment of systemic lupus erythematosus
Pan, L., Lu, M.-P., Wang, J.-H., Xu, M., & Yang, S.-R. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-019-00229-3 · Cited by 411
The multifunctional protein HMGB1: 50 years of discovery
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00894-6 · Cited by 371
JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation
Lu, B., Antoine, D. J., Kwan, K., Lundbäck, P., Wähämaa, H., Schierbeck, H., Robinson, M., Van Zoelen, M. A. D., Yang, H., Li, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316925111 · Cited by 366
Pathogenesis of human systemic lupus erythematosus: recent advances
Crispín, J. C., Liossis, S.-N. C., Kis-Toth, K., Lieberman, L. A., Kyttaris, V. C., Juang, Y.-T., & Tsokos, G. C. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.12.005 · Cited by 359
The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases
Magna, M., & Pisetsky, D. S. (2014) · Molecular Medicine · doi:10.2119/molmed.2013.00164 · Cited by 358
High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule
Yang, H., Wang, H., Chavan, S. S., & Andersson, U. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00087 · Cited by 357
Molecular mechanisms of late apoptotic/necrotic cell clearance
Poon, I. K. H., Hulett, M. D., & Parish, C. R. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.195 · Cited by 354
DAMPs, MAMPs, and NAMPs in plant innate immunity
Choi, H. W., & Klessig, D. F. (2016) · BMC Plant Biology · doi:10.1186/s12870-016-0921-2 · Cited by 349
Bianchi, M. E., Crippa, M. P., Manfredi, A. A., Mezzapelle, R., Rovere Querini, P., & Venereau, E. (2017) · Immunological Reviews · doi:10.1111/imr.12601 · Cited by 330
Self-citationT Lymphocyte Priming by Neutrophil Extracellular Traps Links Innate and Adaptive Immune Responses
Tillack, K., Breiden, P., Martin, R., & Sospedra, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103414 · Cited by 327
High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells
Andersson, U., Yang, H., & Harris, H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.011 · Cited by 309
Interleukin-33 – cytokine of dual function or novel alarmin?
Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., & Küchler, A. M. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.03.003 · Cited by 308
Endometriosis, a disease of the macrophage
Capobianco, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00009 · Cited by 304
Hreggvidsdottir, H. S., Östberg, T., Wähämaa, H., Schierbeck, H., Aveberger, A.-C., Klevenvall, L., Palmblad, K., Ottosson, L., Andersson, U., & Harris, H. E. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908548 · Cited by 290
Extracellular HMGB1 as a therapeutic target in inflammatory diseases
Andersson, U., Yang, H., & Harris, H. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439924 · Cited by 287
Dangers Within: DAMP Responses to Damage and Cell Death in Kidney Disease
Rosin, D. L., & Okusa, M. D. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040430 · Cited by 284
The immune response to secondary necrotic cells
Sachet, M., Liang, Y. Y., & Oehler, R. (2017) · Apoptosis · doi:10.1007/s10495-017-1413-z · Cited by 282
“Chronic secondary necrosis with persistent release of HMGB1–nucleosome complexes [37] might overcome this anti-inflammatory regulation.”
BackgroundInfluentialSrikrishna, G., & Freeze, H. H. (2009) · Neoplasia · doi:10.1593/neo.09284 · Cited by 275
Danger-associated molecular patterns in Alzheimer’s disease
Venegas, C., & Heneka, M. T. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0416-204r · Cited by 236
HMGB1 in Development and Diseases of the Central Nervous System
Fang, P., Schachner, M., & Shen, Y.-Q. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8264-y · Cited by 193
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
Zhang, W., Xu, W., & Xiong, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904016 · Cited by 177
“Notably, TNF-a, IL-6, IL-10, and MCP-1, which could be induced by ALD-DNA, are elevated in the serum of patients with SLE and may contribute to the pathogenesis of SLE (66, 67).”
BackgroundDanger‐associated molecular patterns ( DAMPs ) in acute lung injury
Tolle, L. B., & Standiford, T. J. (2013) · The Journal of Pathology · doi:10.1002/path.4124 · Cited by 157
Bianchi, M. E., & Manfredi, A. A. (2009) · Science · doi:10.1126/science.1172794 · Cited by 117
Self-citationSiglec-G/10 in self-nonself discrimination of innate and adaptive immunity
Chen, G.-Y., Brown, N. K., Zheng, P., & Liu, Y. (2014) · Glycobiology · doi:10.1093/glycob/cwu068 · Cited by 90
Rekvig, O. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569234 · Cited by 42
Metadata
- Authors
- Urbonaviciute, V., Fürnrohr, B. G., Meister, S., Munoz, L., Heyder, P., De Marchis, F., Bianchi, M. E., Kirschning, C., Wagner, H., Manfredi, A. A., Kalden, J. R., Schett, G., Rovere-Querini, P., Herrmann, M., & Voll, R. E.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-12-08
- Volume
- 205
- Issue
- 13
- Pages
- 3007-3018
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2161367998
- Cited by
- 517
- References
- 68
- FWCI
- 27.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.